Rada Miran, Lazaris Anthoula, Kapelanski-Lamoureux Audrey, Mayer Thomas Z, Metrakos Peter
Cancer Research Program, McGill University Health Centre Research Institute, Montreal, Quebec, H4A3J1, Canada.
Cancer Research Program, McGill University Health Centre Research Institute, Montreal, Quebec, H4A3J1, Canada.
Semin Cancer Biol. 2021 Jun;71:52-64. doi: 10.1016/j.semcancer.2020.09.001. Epub 2020 Sep 10.
Vessel co-option is an alternative strategy by which tumour cells vascularize and gain access to nutrients to support tumour growth, survival and metastasis. In vessel co-option, the cancer cells move towards the pre-existing vasculature and hijack them. Vessel co-option is adopted by a wide range of human tumours including colorectal cancer liver metastases (CRCLM) and is responsible for the effectiveness of treatment in CRCLM. Furthermore, vessel co-option is an intrinsic feature and an acquired mechanism of resistance to anti-angiogenic treatment. In this review, we describe the microenvironment, the molecular players, discovered thus far of co-opting CRCLM lesions and propose a theoretical model. We also highlight key unanswered questions that are critical to improving our understanding of CRCLM vessel co-option and for the development of effective approaches for the treatment of co-opting tumours.
血管共生是一种替代策略,肿瘤细胞通过该策略形成血管并获取营养物质以支持肿瘤生长、存活和转移。在血管共生过程中,癌细胞向预先存在的脉管系统移动并加以利用。包括结直肠癌肝转移(CRCLM)在内的多种人类肿瘤都会采用血管共生策略,这也是CRCLM治疗有效的原因。此外,血管共生是抗血管生成治疗的一种内在特征和获得性耐药机制。在本综述中,我们描述了CRCLM病变血管共生的微环境、迄今发现的分子参与者,并提出了一个理论模型。我们还强调了一些关键的未解决问题,这些问题对于增进我们对CRCLM血管共生的理解以及开发治疗血管共生肿瘤的有效方法至关重要。